Loading data for MNPR — first visit, this takes a few seconds.
Monopar Therapeutics Inc.
70.54 -0.11 (-0.16%)
- Market Cap
- $473.5M
- Volume
- 79K
- Dividend yield
- 0.00%
- Next earnings date
- Nov 12, 2026
Monopar Therapeutics Inc. (MNPR) Stock Price, Analysis & Data
Intrinsic value
See plans →Analyst Forecast
Stock Forecasts →$119.00 – $145.00
Median $130.00 · 84.29% upside
You're seeing the free overview
Create a free account to explore more research on this ticker.
Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.62 | +$0.03 | -77.14% |
Metrics
- Bid
- 71.26
- Market Cap
- 473M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -17.8M
- 1.51
- -2.2
- n/a
- -36.82
- P/B (ttm)
- 3.62
- P/S (ttm)
- n/a
- Earnings Date
- Nov 12, 2026
- Ask
- 70.7
- Volume
- 79,014
- Avg. Volume (20D)
- 190,740
- Open
- 71.01
- Previous Close
- 70.65
- Day's Range
- 69.33 - 71.85
- 52-Week Range
- 50.07 - 124.82
- Analyst
- n/a
- Price Target
- 130 (84.29%)
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Monopar Therapeutics Inc.
View profile →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2019
Employees 22
Stock Exchange NasdaqCM
Ticker Symbol MNPR
Website https://www.monopartx.com